Edition:
United States

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
23 Feb 2018
Change (% chg)

$-0.00 (-0.58%)
Prev Close
$0.31
Open
$0.31
Day's High
$0.31
Day's Low
$0.31
Volume
15,066
Avg. Vol
273,820
52-wk High
$2.05
52-wk Low
$0.24

Chart for

About

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more... (more)

Overall

Beta: -0.01
Market Cap(Mil.): $16.36
Shares Outstanding(Mil.): 52.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 49.98 16.31
EPS (TTM): -- -- --
ROI: -- 14.18 35.74
ROE: -- 16.80 17.71

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

Feb 06 2018

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

Jan 24 2018

BRIEF-Trovagene Prices $4.5 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 15 MILLION SHARES OF ITS COMMON STOCK, COMMON WARRANTS TO PURCHASE UP TO 15 MILLION SHARES OF COMMON STOCK

Dec 15 2017

BRIEF-Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of Pcm-075 In Combination With Zytiga®

* TROVAGENE SUBMITS PROTOCOL TO FDA FOR PHASE 2 CLINICAL TRIAL OF PCM-075 IN COMBINATION WITH ZYTIGA® FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Dec 14 2017

BRIEF-Trovagene's preclinical data to be featured at San Antonio Breast Cancer Symposium

* TROVAGENE PRESENTS DATA SHOWING SENSITIVITY OF TRIPLE NEGATIVE BREAST CANCER (TNBC) CELL LINES TO PCM-075 AND SYNERGY WITH ZYTIGA® AT SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) Source text for Eikon: Further company coverage:

Dec 07 2017

BRIEF-Trovagene Inc updates on clinical trial for PCM-075

* Trovagene announces activation of first clinical trial site in phase 1B/2 acute myeloid leukemia (AML) trial for PCM-075

Nov 13 2017

BRIEF-TROVAGENE REPORTS Q3 LOSS PER SHARE $0.12

* ‍AS OF SEPTEMBER 30, 2017, TROVAGENE HAD APPROXIMATELY $7.4 MILLION OF CASH AND CASH EQUIVALENTS​ Source text: (http://bit.ly/2hgteK4) Further company coverage:

Nov 09 2017

BRIEF-Trovagene files for offering of up to $17.5 mln- SEC filing

* Trovagene Inc files for offering of up to $17.5 million - SEC filing Source text: (http://bit.ly/2zOQs1P) Further company coverage:

Oct 25 2017

BRIEF-Trovagene's PCM-075 demonstrates Synergy with Zytiga

* Trovagene Inc - ‍announced positive data from preclinical research demonstrating synergy of PCM-075 in combination with abiraterone (Zytiga)​

Oct 18 2017

BRIEF-Fda grants orphan drug designation to Trovagene's PLK1 inhibitor, PCM-075

* Fda grants orphan drug designation to trovagene's PLK1 inhibitor, PCM-075, for the treatment of acute myeloid leukemia (AML)

Oct 09 2017

Earnings vs. Estimates